This effect has been associated with the inhibitory action of metformin on the MAPK/ERK pathway, which is overactivated in melanomas due to mutations in BRAF, NRAS, and NF1 and promotes increased cell proliferation and expression of EMT-inducing transcription factors24,25. The gene discussed is NRAS; the disease is melanoma.